July 29, 2014 5:30 PM ET


Company Overview of GlycoRegImmune, Inc.

Company Overview

GlycoRegImmune, Inc., a biotech company, develops natural killer T (NKT) cells targeted therapies for liver disease, autoimmune disorders, and ischemic reperfusion injury. Its programs include NKT I cell inhibitors and NKT II cell modulators. The company is based in San Diego, California.

General Atomics Court


Suite 2-203

San Diego, CA 92121

United States



Key Executives for GlycoRegImmune, Inc.

Chief Medical officer
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
PharMingen United States
Encysive Pharmaceuticals Inc. United States
CRL Transaction Co., Inc. United States
SynerGene Therapeutics, Inc. United States
Apollo Biosciences, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlycoRegImmune, Inc., please visit glycoregimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.